MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Spondyloarthritis Studies and Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,117 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,117 works in the cohort · of 4,299,418page 1 of 63

Labels cover 10 of 3,117 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,117 of 3,117 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
2017· review· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
1,365
citations
affunlabeled
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler, Maureen Dubreuil, David Tak Yan Yu, Muhammad Asim Khan +17 more
2019· review· en· Arthritis Care & Research· Medicine
distilled prediction:candidate · metaepi_narrow+stsconsensus · none
692
citations
affunlabeled
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh, Iain B. McInnes, L. Puig, Shu Li +5 more
2014· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · noneconsensus · none
658
citations
affunlabeled
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease, Désirée van der Heijde, Masato Okada, Raquel Cuchacovich, Catherine L Shuler, Chen‐Yen Lin +3 more
2016· article· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · noneconsensus · none
568
citations
affunlabeled
Treatment recommendations for psoriatic arthritis
Christopher T. Ritchlin, Arthur Kavanaugh, Dafna D. Gladman, Philip J. Mease, Philip Helliwell, Kurt de Vlam +8 more
2008· review· en· Annals of the Rheumatic Diseases· Medicine
distilled prediction:candidate · noneconsensus · none
561
citations
affno abstractunlabeled
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, Philip J. Mease, Atul Deodhar, Walter P. Maksymowych +82 more
2018· article· en· The Lancet· Medicine
distilled prediction:candidate · noneconsensus · none
359
citations
next →

How this was built: Screen · Findings · About